Christopher Drake
Investigator · Henry Ford Medical Center - Columbus · Henry Ford Health System
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christopher Drake as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05668754 · Study of SDX in Patients With Idiopathic Hypersomnia (IH)Zevra Therapeutics · completed · Idiopathic Hypersomnia · principal investigator
- N/ANCT02988375 · Sleep to Prevent Evolving Affecting DisordersHenry Ford Health System · completed · Insomnia, Primary, Depression · principal investigator
- N/ANCT01933295 · Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime OutcomesChristopher Drake · completed · Menopause · principal investigator
- N/ANCT00688025 · Magnetoencephalographic (MEG) Localization of Ramelteon's Effects on Brain Function and Cortical Arousal in InsomniaHenry Ford Health System · completed · Insomnia · principal investigator
- N/ANCT00688142 · Sleepiness and Brain Function: The Effect of Armodafinil in Shift Work Sleep DisorderHenry Ford Health System · completed · Shift Work Sleep Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Sleep to Reduce Incident Depression Effectively in Peripartum - (STRIDE P)R01MH129549 · NIMH · HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES · fiscal years 2024 to 2026 · $977,813 awarded in 2026Same name and institution; not confirmed by an ID
- Sleep to Reduce Incident Depression Effectively (STRIDE)R01MH122636 · NIMH · HENRY FORD HEALTH SYSTEM · fiscal years 2020 to 2022 · $607,279 awarded in 2022Same name and institution; not confirmed by an ID
- ConProject-001R56MH115150 · NIMH · HENRY FORD HEALTH SYSTEM · fiscal years 2018 to 2019 · $416,018 awarded in 2019Same name and institution; not confirmed by an ID
- Behavioral Treatment of Menopausal Insomnia; Sleep, Depression, Daytime OutcomesR01NR013959 · NINR · HENRY FORD HEALTH SYSTEM · fiscal years 2013 to 2017 · $405,461 awarded in 2017Grant number is on one of their registry trials
- Longitudinal Study of Predisoposition and Life Events in Triggering InsomniaR01MH082785 · NIMH · HENRY FORD HEALTH SYSTEM · fiscal years 2009 to 2013 · $313,276 awarded in 2013Same name and institution; not confirmed by an ID
- Predisposition Model of InsomniaK23MH068372 · NIMH · HENRY FORD HEALTH SYSTEM · fiscal years 2004 to 2008 · $146,664 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:10 UTC. The ranking covers the 200 most relevant of 99 PubMed records, and a shared surname and initials can bring in a namesake. All 99 on PubMed
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med · 201210,484 citationsRCR 282.6
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med · 20126,565 citationsRCR 174.5
- Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.J Clin Oncol · 20102,518 citationsRCR 55.7
- 1,256 citationsRCR 33.8
- 648 citationsRCR 18.9
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.J Clin Oncol · 2020632 citationsRCR 25.6
- Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.Clin Cancer Res · 2013438 citationsRCR 10.9
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.J Clin Oncol · 2015370 citationsRCR 10.2
- Effect of Digital Cognitive Behavioral Therapy for Insomnia on Health, Psychological Well-being, and Sleep-Related Quality of Life: A Randomized Clinical Trial.JAMA Psychiatry · 2019342 citationsRCR 22.6
- 304 citationsRCR 8.8